Shayla Bergmann
Pediatric Hematology-Oncology · Beaufort, SCNPI 1730143645
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 76.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $93,552 and has fallen 65.0% since, to $32,787 in 2025. Among pediatric hematology-oncology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $1172.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$219K
- Novartis$20K
- Sanofi$16K
- Genentech USA, Inc.$12K
- Sobi, Inc$6K
- Shire North American Group Inc$5K
- plus $9K from 9 others
Across 451 payments — averaging $4226.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$580K
- Takeda Pharmaceuticals U.S.A., Inc.$439K
- Global Blood Therapeutics, Inc.$345K
- Pfizer$288K
- CSL Behring$109K
- Novo Nordisk AS$45K
- plus $100K from 5 others
What the payments were for
- Consulting fees$70,93425%
- Speaking & faculty fees$169,31959%
- Travel & lodging$41,05214%
- Food & beverage$5,9462%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 161 | $219,365 |
| Novartis | 25 | $19,629 |
| Sanofi | 12 | $15,537 |
| Genentech USA, Inc. | 18 | $12,100 |
| Sobi, Inc | 7 | $5,954 |
| Shire North American Group Inc | 3 | $5,277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $4,511 |
| Bayer | 3 | $2,406 |
| Chiesi USA, Inc. | 1 | $2,100 |
| AstraZeneca | 1 | $150 |
| Biomarin Pharmaceutical Inc. | 1 | $131 |
| GSK | 3 | $50 |
| Pfizer | 4 | $40 |
| Boston Scientific | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$287,290 in reported general payments places this provider in the 95th percentile of 32 pediatric hematology-oncology providers in South Carolina.
See all pediatric hematology-oncology providers in South Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydromorphone Hcl | 16 | $223 |
| Methadone Hcl | 12 | $132 |
| Oxycodone Hcl | 12 | $131 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Beaufort
- Alan AndersonGreenville$320K
- Jacqueline KravekaCharleston$36K
- Stephaine AmbroseColumbia$33K
- Michelle HudspethCharleston$25K
- Miguel AbboudCharleston$15K
- Howland CrosswellGreenville$14K
- Leslie GilbertGreenville$8K
- Christina AbramsCharleston$7K
- Evangeline BrownColumbia$7K
- Brianna MurphyGreenville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.